Urinary protein profiling by liquid chromatography/tandem mass spectrometry: ADAM28 is overexpressed in bladder transitional cell carcinoma

Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Taiwan.
Rapid Communications in Mass Spectrometry (Impact Factor: 2.25). 10/2011; 25(19):2851-62. DOI: 10.1002/rcm.5169
Source: PubMed


Bladder cancer is the most common urological cancer with higher incidence rate in the endemic areas of Blackfoot disease (BFD) in southern Taiwan. The aim of this study was to utilize the proteomic approach to establish urinary protein patterns of bladder cancer. The experimental results showed that most patients with bladder cancer had proteinuria or albuminuria. The urine arsenic concentrations of bladder cancer patients in BFD areas were significantly higher than those patients from non-BFD areas. In the proteomic analysis, the urinary proteome was identified by nano-high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (nano-HPLC/ESI-MS/MS) followed by peptide fragmentation pattern analysis. We categorized 2782 unique proteins of which 89 proteins were identified with at least three unique matching peptide sequences. Among these 89 proteins, thirteen of them were not found in the control group and may represent proteins specific for bladder cancer. In this study, three proteins, SPINK5, ADAM28 and PTP1, were also confirmed by Western blotting and showed significant differential expression compared with the control group. ADAM28 may be used as a possible biomarker of bladder cancer.

Download full-text


Available from: Yu-Chang Tyan, Oct 16, 2014
  • Source
    • "Among them ADAM28 may serve as a possible biomarker of bladder cancer (Tyan et al., 2011). Soluble Fas (sFas): it has been shown to be made and released by bladder TCC cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: As the recurrence and mortality rates of bladder cancer are high, research is needed to find suitable biomarkers for early detection, evaluation of prognosis, and surveillance of drug responses. We performed a computerized search of the Medline/PubMed databases with the key words bladder cancer, biomarker, early detection, prognosis and drug response. Several markers were identified at DNA, RNA and protein levels with different sensitivities and specificities. Only a few of the potential bladder cancer biomarkers have been approved for clinical use. Efforts now should be concentrated on finding a panel of markers with acceptable sensitivity and specificity for early detection of bladder cancer.
    Full-text · Article · Mar 2014 · Asian Pacific journal of cancer prevention: APJCP
  • Source
    • "Among these, proteins are the final biological factors for performing biochemical reactions and physiological responses. Several studies have reported the unique proteomic profiling of pleural effusion [9] [10] or urine [11] [12]. Analyzing proteomic presentation of the dialysate may provide clues for both understanding the mechanisms of peritoneal damages and noninvasively predicting the changes of peritoneal transport characters. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Peritoneal dialysis (PD) is an increasingly accepted modality of renal replacement therapy. It provides the advantages of having a flexible lifestyle, stable hemodynamics, and better preservation of residual renal function. To enhance our understanding of the peritoneal dialysate of diabetes mellitus (DM), peritoneal dialysate proteins were identified by two-dimensional gel electrophoresis (2DE) combined with reverse-phase nano-ultra performance liquid chromatography electrospray ionization tandem mass spectrometry (RP-nano-UPLC-ESI-MS/MS) followed by peptide fragmentation patterning. To validate the differential proteins, ELISA and Western blotting analyses were applied to detect candidate proteins that may be related to DM. We performed 2DE on the peritoneal dialysate samples, with detection of more than 300 spots. From this, 13 spots were excised, in-gel digested, and identified by RP-nano-UPLC-ESI-MS/MS. Ten of these showed significant differential expression between the DM and chronic glomerulonephritis (CGN) peritoneal dialysate samples. In this study, we conducted a comparative proteomic study on these two groups of dialysate that may provide evidence for understanding the different peritoneal protein changes. These proteins may not be new biomarkers; however, they may indicate a situation for possible drug treatment and can be the predictors of peritonitis for a validation study in the future.
    Full-text · Article · May 2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent progress in quantitative proteomics has offered opportunities in discovering plasma proteins as biomarkers to track the progression and understand the molecular mechanisms of bladder transitional cell carcinoma (TCC). In this study, differential plasma protein levels and redox regulation were analyzed by lysine- and cysteine-labeling two-dimensional differential gel electrophoresis (2D-DIGE), and combined with matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS/MS). This study shows 50 and 34 plasma protein features that were significantly changed in protein expression and thiol reactivity, respectively, and shows that plasma proteins involved in inflammatory responses are up-regulated in bladder TCC. In contrast, plasma proteins responsible for cytoskeleton and cytoskeleton regulation are down-regulated. In addition, plasma proteins involving cell adhesion, inflammatory responses, protease inhibitors, and plasma protein transport are shown to be altered in their thiol reactivity. In summary, we perform a comprehensive patient-based plasma proteomic approach for the identification of potential plasma biomarkers in bladder TCC screening and detection.
    Full-text · Article · Oct 2012 · Molecular BioSystems
Show more